Home Cart Sign in  
Chemical Structure| 16503-32-5 Chemical Structure| 16503-32-5

Structure of Brevilin A
CAS No.: 16503-32-5

Chemical Structure| 16503-32-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Brevilin A, a natural product isolated and purified from the herbs of Centipeda minima, is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperactivated JAKs and STATs, and has antigiardial activity (IC50 = 16.1 μM) and was similarly active in vitro against Entamoeba histolytica (IC50 between 4.5 and 9 μM) and against Plasmodium falciparum (IC50 = 9.42 μM).

Synonyms: 6-O-Angeloylprenolin; 6-O-Angeloylplenolina; 6-O-Angeloylplenolin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Brevilin A

CAS No. :16503-32-5
Formula : C20H26O5
M.W : 346.42
SMILES Code : C/C=C(C)\C(O[C@@H]([C@@]([C@@H]1C)([H])[C@]2([H])OC1=O)[C@]3(C)C(C=C[C@@]3([H])[C@H](C)C2)=O)=O
Synonyms :
6-O-Angeloylprenolin; 6-O-Angeloylplenolina; 6-O-Angeloylplenolin
MDL No. :MFCD04034623
InChI Key :KUPPZVXLWANEJJ-UXPPPGSFSA-N
Pubchem ID :12302076

Safety of Brevilin A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Brevilin A

JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW264.7 macrophages (TNFα/IFNγ stimulated) 1, 2, 5 μM 1 h Significantly inhibited TNFα/IFNγ-induced NO production Front Pharmacol. 2022 Jun 14;13:911157
BMDMs (bone-marrow derived macrophages) 1, 2, 5 μM 1 h Significantly inhibited LPS/IFNγ-induced NO production Front Pharmacol. 2022 Jun 14;13:911157
RAW264.7 macrophages 1, 2, 5 μM 1 h Inhibited NO and PGE2 production, downregulated iNOS and COX2 expression, suppressed mRNA expression of IL-1β, IL-6, and TNFα Front Pharmacol. 2022 Jun 14;13:911157
A549/T lung cancer cells 5, 10, 15 µM 24 h Brevilin A significantly inhibited the proliferation and growth of A549/T cells and induced apoptosis. Front Pharmacol. 2022 Feb 24;13:795613
Madin-Darby canine kidney (MDCK) epithelial cells 8 µM 4-8 h Inhibited replication of H1N1, H3N2, and H9N2 influenza viruses, reduced viral RNA synthesis, viral mRNA expression, and nuclear export of viral ribonucleoproteins (vRNPs). Viruses. 2019 Sep 8;11(9):835
A549 cells 0, 20, 30, 40, 50 µM 12 h To evaluate the ability of BLN-A to induce apoptosis, results showed that BLN-A induced apoptosis in A549 cells in a dose-dependent manner. J Cancer. 2020 Apr 6;11(13):3725-3735
NCI-H1650 cells 0, 5, 15, 30, 60, 100 µM 12 h To evaluate the inhibitory effect of BLN-A on cell proliferation, results showed that BLN-A inhibited the proliferation of NCI-H1650 cells in a dose-dependent manner. J Cancer. 2020 Apr 6;11(13):3725-3735
A549 cells 0, 5, 15, 30, 60, 100 µM 12 h To evaluate the inhibitory effect of BLN-A on cell proliferation, results showed that BLN-A inhibited the proliferation of A549 cells in a dose-dependent manner. J Cancer. 2020 Apr 6;11(13):3725-3735
L929 mouse fibroblasts 200 mg/mL 24 h Evaluate cytotoxicity, results showed cell viability of 82.25 ± 2.5%, indicating low cytotoxicity Gels. 2024 Mar 24;10(4):219
RAW264.7 cells 200 mg/mL 24 h Evaluate anti-inflammatory activity, results showed BA/COs/NO-PL/AL significantly inhibited LPS-induced IL-6 production Gels. 2024 Mar 24;10(4):219
NCM460 57.24 μM 24h To evaluate the effect of Brevilin A on the viability of NCM460 cells, results showed that Brevilin A exhibited relatively less cytotoxicity to colon epithelial cells compared to CRC cells. J Transl Med. 2023 Apr 16;21(1):260
HT-29 16.70 μM (24h), 3.05 μM (48h) 24h and 48h To evaluate the effect of Brevilin A on the viability of HT-29 cells, results showed that Brevilin A reduced CRC cell viability in a dose-dependent manner. J Transl Med. 2023 Apr 16;21(1):260
LOVO 8.73 μM (24h), 2.82 μM (48h) 24h and 48h To evaluate the effect of Brevilin A on the viability of LOVO cells, results showed that Brevilin A reduced CRC cell viability in a dose-dependent manner. J Transl Med. 2023 Apr 16;21(1):260
CT26 21.53 μM (24h), 9.67 μM (48h) 24h and 48h To evaluate the effect of Brevilin A on the viability of CT26 cells, results showed that Brevilin A reduced CRC cell viability in a dose-dependent manner. J Transl Med. 2023 Apr 16;21(1):260
HCT-116 20.98 μM (24h), 8.94 μM (48h) 24h and 48h To evaluate the effect of Brevilin A on the viability of HCT-116 cells, results showed that Brevilin A reduced CRC cell viability in a dose-dependent manner. J Transl Med. 2023 Apr 16;21(1):260

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR and C57BL/6 mice LPS-induced acute lung injury model Intraperitoneal injection 20 mg/kg Administered 2 h before LPS exposure, and again at 6 and 18 h after LPS challenge Attenuated LPS-induced lung damage, inflammatory infiltration, and production of pro-inflammatory cytokines (MPO, IL-1β, IL-6, TNFα, and PGE2) Front Pharmacol. 2022 Jun 14;13:911157
BALB/c mice Influenza A/PR/8/34 (H1N1) virus infection model Intraperitoneal injection 25 mg/kg Starting 1 hour post-infection, once every other day for 6 days Evaluated the protective effect of Brevilin A in influenza virus-infected mice, showing that the 25 mg/kg dose group significantly delayed time-to-death with 50% survival up to 14 days post-infection. Viruses. 2019 Sep 8;11(9):835
BALB/c mice CRC liver metastasis model and xenograft model Intraperitoneal injection 4 mg/kg and 8 mg/kg Once daily for 2 consecutive weeks To evaluate the effect of Brevilin A on CRC liver metastasis and tumor growth, results showed that Brevilin A significantly inhibited colorectal liver metastasis and cancer growth. J Transl Med. 2023 Apr 16;21(1):260

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.43mL

2.89mL

1.44mL

28.87mL

5.77mL

2.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories